-
Mashup Score: 2Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens - 2 year(s) ago
Summary: For too long, assays exposing patient tumor cells to drugs to identify active therapies have been dismissed as ineffective. In this issue of Cancer Discovery , two groups independently demonstrate clinical utility of such functional precision medicine assays in hematologic malignancies. See related article by Kornauth et al., [p. 372][1] . See related article by Malani et al., [p….
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens - 2 year(s) ago
Summary: For too long, assays exposing patient tumor cells to drugs to identify active therapies have been dismissed as ineffective. In this issue of Cancer Discovery , two groups independently demonstrate clinical utility of such functional precision medicine assays in hematologic malignancies. See related article by Kornauth et al., [p. 372][1] . See related article by Malani et al., [p….
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the Spotlight: Shedding light on ecDNA behavior using CRISPR-based live cell imaging by @anton_gh @ChariteBerlin @MDC_Berlin. https://t.co/ES7Ffvc71I https://t.co/6p1zLrQp2s
-
-
Mashup Score: 7Cancer Discovery: 12 (2) - 2 year(s) ago
New therapeutic advances are needed for acute myeloid leukemia (AML) given low rates of cure using standard therapies. Two studies by Kornauth, Pemovska, Vladimer, and colleagues (page 372) and Malani and colleagues (page 388) deployed drug sensitivity testing to…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out the papers featured on the cover of this month’s Cancer Discovery: Individualized therapies for hematologic malignancies. https://t.co/okXSk53ST6 By @CK5haus, @TPemovska, Ingrid Simonitsch-Klupp, @giuliosf, @BerendSnijder, @PhilippStaber, and colleagues ⬇ https://t.co/dcMfGGHi4D
-
-
Mashup Score: 5Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer - 2 year(s) ago
Gastric cancer heterogeneity represents a barrier to disease management. We generated a comprehensive single-cell atlas of gastric cancer (>200,000 cells) comprising 48 samples from 31 patients across clinical stages and histologic subtypes. We identified 34 distinct cell-lineage states including novel rare cell populations. Many lineage states exhibited distinct cancer-associated expression…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
Really nice work as usual from the Tan group. Great resource. @CD_AACR Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer https://t.co/jTZIvqlLs4
-
-
Mashup Score: 0In This Issue - 2 year(s) ago
![][1] CDK4/6 inhibitors (CDK4/6i) are standard of care for treating hormone receptor–positive breast cancer; however, resistance to these drugs is commonly observed. The mechanisms of resistance to CDK4/6i are not well established, hampering development of more effective strategies
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read article highlights from the February issue of Cancer Discovery #InThisIssue. https://t.co/ia7ifVw08W https://t.co/ByJuQIDGpW
-
-
Mashup Score: 0Safety Concerns Prompt Pause of Magrolimab Trials - 2 year(s) ago
Gilead paused enrollment in trials of its anti-CD47 therapy magrolimab following suspicions of a safety issue experienced by patients with acute myeloid leukemia or myelodysplastic syndrome who received it in combination with the chemotherapeutic agent azacitidine.
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NewsInBrief: Safety Concerns Prompt Pause of Magrolimab Trials. https://t.co/IlcKVQ2fHU https://t.co/aL93JkaBXg
-
-
Mashup Score: 4Cancer Discovery: 12 (2) - 2 year(s) ago
…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The February issue of Cancer Discovery is now online! https://t.co/HGIl6MDfQf https://t.co/4EvUpSjaYn
-
-
Mashup Score: 3
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. To discover such interactions, we developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a tool deconvolving cell-type-specific gene expression in each sample from bulk expression, and LIRICS (LIgand Receptor Interactions between Cell Subsets), a statistical…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Deconvolving clinically relevant cellular immune crosstalk from bulk gene expression using CODEFACS and LIRICS stratifies #melanoma patients to anti-PD-1 therapy by Kun Wang, @spatkar94, @NCIEytanRuppin, and colleagues @theNCI, @NCIResearchCtr. https://t.co/xJQYSl7kcO https://t.co/ro8m1hdQK6
-
-
Mashup Score: 9Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements - 2 year(s) ago
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zenocutuzumab, a #HER2 x #HER3 #bispecific antibody, is effective therapy for tumors driven by #NRG1 gene rearrangements by @AliSchram, @Odintsov_I, Romel Somwar, and colleagues @sloan_kettering. https://t.co/bP4m50ITVC https://t.co/SuFrJhmDml
-
-
Mashup Score: 10Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements - 2 year(s) ago
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements @AliSchram @CD_AACR https://t.co/mnZD3QD76g
-
In the Spotlight: Functional Precision Medicine: Putting drugs on patient cancer cells and seeing what happens by @DrTonyLetai, @DanaFarber, @harvardmed. https://t.co/mc8CqbfDQt https://t.co/ChfvQXGmql